test Browse by Author Names Browse by Titles of Works Browse by Subjects of Works Browse by Issue Dates of Works

Advanced Search
& Collections
Issue Date   
Sign on to:   
Receive email
My Account
authorized users
Edit Profile   
About T-Space   

T-Space at The University of Toronto Libraries >
University of Toronto at Scarborough >
Bioline International Legacy Collection >
Bioline International Legacy Collection >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1807/6558

Title: Expression of chimeric HCV peptide in transgenic tobacco plants infected with recombinant alfalfa mosaic virus for development of a plant-derived vaccine against HCV
Authors: El Attar, A. K.
Shamloul, A. M.
Shalaby, A. A.
Riad, B. Y.
Saad, A.
Mazyad, H. M.
Keith, J. M.
Keywords: Hepatitis C virus (HCV), transgenic tobacco plants (P12), consensus HCV HVR1 epitope (R9), and chimeric ALMV-RNA4.
Issue Date: 31-Dec-2004
Publisher: Academic Journals
Citation: African Journal of Biotechnology (ISSN: 1684-5315) Vol 3 Num 11
Abstract: Hepatitis C virus (HCV) is the major etiologic agent of blood transfusion-associated and sporadic non-A non-B hepatitis affecting more than 180 million worldwide. Vaccine development for HCV has been difficult and there is no vaccine or effective therapy against this virus. In this paper, we describe the development of an experimental plant-derived subunit vaccine against HCV. Our subunit vaccine originates from a consensus HCV-HVR1 epitope (R9) that antigenically mimics many natural HVR1 variants. This HVR1 sequence was cloned into the open reading frame of a plant virus, Alfalfa Mosaic Virus (ALMV) coat protein (CP). The chimeric ALMV RNA4 containing sequence-encoding R9 epitope was introduced into full-length infectious ALMV-RNA3 that was utilized as an expression vector. The recombinant chimeric protein is expressed in transgenic tobacco plants (P12) expressing ALMV RNA1 and 2. Plant-derived HVR1/ALMV-CP reacted with HVR1 and/or ALMV-CP specific monoclonal antibodies and immune sera from individuals infected with HCV. Using plant-virus based transient expression to produce this unique chimeric antigen will facilitate the development and production of an experimental HCV vaccine. A plant derived recombinant HCV vaccine can potentially reduce expenses normally associated with production and delivery of conventional vaccine.
URI: http://hdl.handle.net/1807/6558
Other Identifiers: http://www.bioline.org.br/abstract?id=jb04117
Rights: Copyright 2004 - Academic Journals
Appears in Collections:Bioline International Legacy Collection

Files in This Item:

File Description SizeFormat
jb04117.pdf259.93 kBAdobe PDF

Items in T-Space are protected by copyright, with all rights reserved, unless otherwise indicated.